Just a day after GlaxoSmithKline and Vir Biotechnology’s Covid-19 antibody fell flat in an NIH-sponsored trial for hospitalized patients, researchers have ejected another therapy from the study. Is this the death knell for monoclonal antibodies for those patients?
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,